CORONA REMEDIES LIMITED CORONA NSEPHARMA
Company Overview
CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women's healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India.
Why Investors Should Care
Generates a return on equity of 24.8%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 29.0%.
Net profit has compounded at 29.7% per year over the last five years.
Revenue has grown at a 16.6% CAGR over the past five years.
Operating margin of 18.3% supports profitability.
Carries low leverage with a debt-to-equity ratio of 0.22.
Recent Developments
- Mar 2026 Revenue of ₹1,401.48 Cr (+17.2% YoY); net profit ₹185.12 Cr.
- Trailing 12 Months Year-on-year growth — revenue +17.2%, earnings +23.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 16.6%, profit CAGR 29.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 16.62% |
| 1 Year: | 17.23% |
Compounded Profit Growth
| 5 Years: | 29.66% |
| 1 Year: | 23.88% |
Stock Price Performance
| 1 Year: | +46.80% |
| 6 Months: | +34.93% |
| 3 Months: | +19.24% |
| 1 Month: | +2.67% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)52.10 · Neutral
P/E of 69.38 is above the sector median of 41.64 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 24.8%.
- Healthy ROCE of 29.0%.
- Compounding revenue at 16.6% over 5 years.
- Profit CAGR of 29.7% over 5 years.
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 69.4.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CORONA CORONA REMEDIES LIMITED NSEPHARMA | 2,100.10 | 69.38 | ₹12,844.23 Cr | 0.49% | 29.03% | 24.79% | 16.62% | 29.66% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,899.00 | 39.73 | ₹4.56 L Cr | 0.82% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,100.00 | 94.06 | ₹2.42 L Cr | 0.36% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,857.00 | 75.99 | ₹1.64 L Cr | 0.77% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,650.00 | 64.10 | ₹1.24 L Cr | 0.22% | 19.20% | 20.48% | 14.85% | 33.34% |
| 6 | LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA | 684.90 | 236.17 | ₹1.19 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,120.00 | 22.36 | ₹1.13 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,385.00 | 28.85 | ₹1.12 L Cr | 0.88% | 14.86% | 11.27% | 7.23% | 11.45% |
| 9 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 1,840.00 | 111.85 | ₹99,333.61 Cr | 0.13% | 19.53% | 16.77% | 3.77% | 4.00% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 314.00 Cr | 297.69 Cr | 293.69 Cr | 346.29 Cr | 361.00 Cr | 342.42 Cr | 353.09 Cr |
| Cost of Revenue | - | 55.20 Cr | 56.86 Cr | 65.78 Cr | - | 60.27 Cr | 66.24 Cr |
| Gross Profit | - | 242.49 Cr | 236.83 Cr | 280.50 Cr | - | 282.15 Cr | 286.85 Cr |
| Operating Expenses | 247.00 Cr | 182.76 Cr | 192.65 Cr | 219.45 Cr | 283.00 Cr | 208.44 Cr | 235.12 Cr |
| Operating Income | 58.00 Cr | 59.73 Cr | 44.18 Cr | 61.05 Cr | 69.00 Cr | 73.71 Cr | 51.73 Cr |
| EBITDA | 67.00 Cr | 70.36 Cr | 55.85 Cr | 71.00 Cr | 78.00 Cr | 66.32 Cr | 66.41 Cr |
| Interest Expense | 3.00 Cr | 2.39 Cr | 2.20 Cr | 1.39 Cr | 2.00 Cr | 1.66 Cr | 1.38 Cr |
| Pretax Income | 57.00 Cr | 58.28 Cr | 43.61 Cr | 60.69 Cr | 70.00 Cr | 55.21 Cr | 54.74 Cr |
| Tax Provision | 14.25 Cr | 13.33 Cr | 12.06 Cr | 14.50 Cr | 17.50 Cr | 13.94 Cr | 9.41 Cr |
| Net Income | 43.00 Cr | 44.95 Cr | 31.55 Cr | 46.20 Cr | 52.00 Cr | 41.27 Cr | 45.33 Cr |
| Diluted EPS | 7.03 | 7.35 | 5.16 | 7.55 | 8.55 | 6.75 | 7.41 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 883.53 Cr | 1,013.68 Cr | 1,195.51 Cr | 1,401.48 Cr |
| Cost of Revenue | 210.95 Cr | 226.83 Cr | 236.52 Cr | 260.94 Cr |
| Gross Profit | 672.57 Cr | 786.85 Cr | 958.99 Cr | 1,140.54 Cr |
| Operating Expenses | 564.49 Cr | 659.02 Cr | 755.39 Cr | 884.25 Cr |
| Operating Income | 108.09 Cr | 127.83 Cr | 203.60 Cr | 256.29 Cr |
| EBITDA | 133.38 Cr | 158.25 Cr | 243.73 Cr | 282.86 Cr |
| Interest Expense | 2.38 Cr | 11.49 Cr | 8.04 Cr | 4.57 Cr |
| Pretax Income | 110.89 Cr | 118.48 Cr | 198.53 Cr | 240.42 Cr |
| Tax Provision | 25.96 Cr | 27.98 Cr | 49.10 Cr | 55.30 Cr |
| Net Income | 84.93 Cr | 90.50 Cr | 149.43 Cr | 185.12 Cr |
| Diluted EPS | 13.89 | 14.80 | 24.43 | 30.27 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Total Assets | 595.02 Cr | 830.58 Cr | 929.86 Cr | 1,205.14 Cr |
| Current Assets | 291.49 Cr | 289.92 Cr | 338.87 Cr | 348.31 Cr |
| Cash & Equivalents | 14.49 Cr | 3.16 Cr | 3.22 Cr | 1.83 Cr |
| Inventory | 105.40 Cr | 98.34 Cr | 129.48 Cr | 125.00 Cr |
| Receivables | 86.99 Cr | 99.93 Cr | 118.29 Cr | 145.55 Cr |
| Total Liabilities | 186.50 Cr | 350.17 Cr | 323.52 Cr | 458.28 Cr |
| Current Liabilities | 137.37 Cr | 224.19 Cr | 239.59 Cr | 361.17 Cr |
| Long Term Debt | 0 | 67.00 Cr | 16.00 Cr | 0 |
| Total Debt | 27.96 Cr | 158.96 Cr | 86.24 Cr | 164.85 Cr |
| Total Equity | 408.52 Cr | 480.41 Cr | 606.34 Cr | 746.86 Cr |
| Shares Outstanding | 6.12 Cr | 6.12 Cr | 6.12 Cr | 6.12 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating Cash Flow | 102.70 Cr | 156.76 Cr | 190.49 Cr | 229.48 Cr |
| Investing Cash Flow | -50.24 Cr | -266.64 Cr | -83.86 Cr | -256.15 Cr |
| Financing Cash Flow | -44.75 Cr | 98.55 Cr | -106.57 Cr | 25.28 Cr |
| Capital Expenditure | -94.76 Cr | -286.34 Cr | -91.66 Cr | -174.14 Cr |
| Free Cash Flow | 7.94 Cr | -129.58 Cr | 98.83 Cr | 55.34 Cr |
| Net Change in Cash | 7.71 Cr | -11.34 Cr | 6.00 L | -1.39 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Gross Margin % | 76.1% | 77.6% | 80.2% | 81.4% |
| Operating Margin % | 12.2% | 12.6% | 17.0% | 18.3% |
| Net Margin % | 9.6% | 8.9% | 12.5% | 13.2% |
| ROE % | 20.8% | 18.8% | 24.6% | 24.8% |
| ROCE % | 23.6% | 21.1% | 29.5% | 30.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CORONA
This Modelo and Corona Beer Maker Reports Earnings Tuesday. Here's How Much Its Stock Could Move - Investopedia
<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxPRC0yd2dDZTNfeEJKVGE3UEFncXJ2cDE3SXRXWndfcjh5Q2puZ05FVGF4QkwydmM4MW1GRldkLThBSTNOcXJjR2owaklNY3ZneHlPbWloSVpxZk9FdjU1ejBzLUdSTERMUFZJdTlCZFIxcm9xS2FvV1pVaGVxSHk0WThMZV9DdlVLVUp0cU…
Corona maker Constellation Brands tops forecasts as beer business drives earnings growth - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxNdlI5Yms1aG5lMTJOUjdSRm9VVEdDYl80ZTFQWlFjMFdwY0RfWGxQYk96dUNHV3NXZ1o2WWlQS1FOMFFSNVowQXI2dGUtaExabDIwNmRwZ0ZSQ1FaRHZZZS1QdnNsRU5HVUJPQVpOR1FRVUZKSUl6OWxaaDBPRm5kSXdZSERpVlEyNWdXTH…
Jim Cramer Calls Corona Beer Maker Constellation Brands a 'Steal' After Stock Drop - Benzinga
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxQYzhlSTFrVTBQMklfenBZdUNaLW1vUGZqdUhLOFAweXJCSkFPVnRWS2FfSjk0Z2x4QzQxMW9RTWZueGVidUd2UnhwalZwX1VnV2gxMDM1U3AwYlo0M1YtYWNuOU9yVmJwcXdsQWRKN2hyaUxyajNmYXBTbUtfak9lUUJNUVp2eVNfUHJFck…
Corona put its logo on $100 stock photos for latest outdoor ads - Crain's Chicago Business
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxON3BLUkEyUzA4ckw1TGVyZVdtYmUyN01keWdfdnNUV3FVRzlTWV9qNm9wRTdmRHh1NVUyWE1QLTlCTjE2aXlSVVoyMjd0Z3ZQVmpmVjNOTEdaZHV2MTA2RTl3UktxOUJIOXd3aVptV0JQbUlzdU53dUxwb0FjcFlWNWJScnJSNkYtVHVKRT…
Corona Remedies Ltd Dividend History, Yield & Record Date - INDmoney
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE9VVDJ6cmVTZjRQYXFBU1h1RHhDUHIwcVp6ZlBhUURsZHlRa2w0ZS1uZTdPQWdILTZPVmZQdEVCVmNrQUplNjJ1dzN6WlYzbkc2Uzh4a3F5WWRrb28xVi1XYVR0WldTN3hTUDRmODZYY1VKRk0wMERmZg?oc=5" target="_blank">Coron…
CORONA Stock Price and Chart — NSE:CORONA - TradingView
<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE1qR1E1d0JWRExPVXh5NTFPbmZJTjlBbEVrT25KTlJyaXBTYVU2dUttaVpYNTRsZHh4SUpDMWxSM3pGdGdQT2ZKZGJfX0oyVkZFQzRJdE40b0hEb2c?oc=5" target="_blank">CORONA Stock Price and Chart — NSE:CORONA</a…
CORONA — Frequently Asked Questions
What is the current share price of CORONA REMEDIES LIMITED (CORONA)?
As of 2026-09-08 04:53 IST, CORONA REMEDIES LIMITED (CORONA) trades at ₹2,100.10 on NSE. Its 52-week range is ₹1,340.36 to ₹2,165.80.
What is the market capitalisation of CORONA?
CORONA REMEDIES LIMITED (CORONA) has a market capitalisation of ₹12,844.23 Cr on NSE.
What is the P/E ratio of CORONA?
CORONA trades at a trailing price-to-earnings (P/E) ratio of 69.38. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 16.86.
Does CORONA pay a dividend?
CORONA REMEDIES LIMITED (CORONA) currently offers a dividend yield of 0.49%.
What is the return on equity (ROE) of CORONA?
CORONA has a return on equity (ROE) of 24.79%. Its return on capital employed (ROCE) is 29.03%.
Is CORONA a good stock to buy?
This page provides a data-driven analysis of CORONA REMEDIES LIMITED (CORONA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.